REPLIGEN CORP Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount
REPLIGEN CORP (RGEN) reported Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount of $294.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationOtherReconcilingItems · last filed 2026-02-26
- REPLIGEN CORP effective income tax rate reconciliation, other reconciling items, amount for fiscal 2025 was $294.00K, a 188.24% increase from fiscal 2024.
- REPLIGEN CORP effective income tax rate reconciliation, other reconciling items, amount for fiscal 2024 was $102.00K, a 36.65% decline from fiscal 2023.
- REPLIGEN CORP effective income tax rate reconciliation, other reconciling items, amount for fiscal 2023 was $161.00K.
- REPLIGEN CORP effective income tax rate reconciliation, other reconciling items, amount for fiscal 2022 was -$92.00K, a 112.60% decline from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount 12 month | Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $294.00K 10-K · filed 2026-02-26 | |
| 2024-12-31 | $102.00K 10-K · filed 2025-03-14 | |
| 2023-12-31 | $161.00K 10-K · filed 2025-03-14 | $765.00K 10-K · filed 2024-02-22 |
| 2022-12-31 | -$92.00K 10-K · filed 2025-03-14 | -$592.00K 10-K · filed 2023-02-22 |
| 2021-12-31 | $730.00K 10-K/A · filed 2024-11-18 | $0.00 10-K · filed 2022-02-17 |
| 2020-12-31 | $1.39M 10-K · filed 2023-02-22 | $578.00K 10-K · filed 2021-02-24 |
| 2019-12-31 | -$218.00K 10-K · filed 2022-02-17 | |
| 2018-12-31 | -$1.00K 10-K · filed 2021-02-24 | |
| 2017-12-31 | $222.00K 10-K · filed 2020-02-26 | -$151.00K 10-K · filed 2018-02-22 |
| 2016-12-31 | $43.00K 10-K · filed 2019-03-01 | |
| 2015-12-31 | -$358.00K 10-K · filed 2018-02-22 | |
| 2014-12-31 | -$25.00K 10-K · filed 2017-02-23 | -$24.88K 10-K · filed 2015-03-17 |
| 2013-12-31 | $9.00K 10-K · filed 2016-02-25 | $83.71K 10-K · filed 2014-03-14 |
| 2012-12-31 | -$149.70K 10-K · filed 2015-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |